Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017–2018

References

• CDC. Burden of Influenza. Centers for Disease Control and Prevention; 2011 June 11 [Accessed 2021 July 19]. https://www.cdc.gov/flu/about/burden/index.html.
   Google Scholar
• Appiah GD, Chung JR, Flannery B, Havers FP, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K. et al. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011‐12—2015‐16. Influenza Other Respir Viruses. 2019;13(2):133–7. doi:10.1111/irv.12616.
   Web of Science ®Google Scholar
• Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z, Rankin D, Halasa N, Talbot HK, Reed C. et al. Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States. Emerg Infect Dis. 2020;26(8):1720–30. doi:10.3201/eid2608.191493.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2022–23 influenza season. MMWR Recomm Rep. 2022;71(1):1–28. doi:10.15585/mmwr.rr7101a1.
   PubMedGoogle Scholar
• Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012;17(6):601–8. doi:10.1097/MOT.0b013e3283592622.
   PubMed Web of Science ®Google Scholar
• Piñana JL, Pérez A, Montoro J, Giménez E, Gómez MD, Lorenzo I, Madrid S, González EM, Vinuesa V, Hernández-Boluda JC. et al. Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: a cross-sectional, prospective, observational study. Clin Infect Dis. 2019;68(11):1894–903. doi:10.1093/cid/ciy792.
   PubMed Web of Science ®Google Scholar
• Hanitsch LG, Löbel M, Mieves JF, Bauer S, Babel N, Schweiger B, Wittke K, Grabowski P, Volk H-D, Scheibenbogen C. et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016;34(21):2417–23. doi:10.1016/j.vaccine.2016.03.091.
   Web of Science ®Google Scholar
• Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H. Influenza vaccination in adult patients with solid tumours treated with chemotherapy. Eur J Cancer. 2017;76:134–43. doi:10.1016/j.ejca.2017.02.012.
   PubMed Web of Science ®Google Scholar
• Garg S, Thongcharoen P, Praphasiri P, Chitwarakorn A, Sathirapanya P, Fernandez S, Rungrojcharoenkit K, Chonwattana W, Mock PA, Sukwicha W. et al. Randomized controlled trial to compare immunogenicity of standard-dose intramuscular versus intradermal trivalent inactivated influenza vaccine in HIV-Infected men who have sex with men in Bangkok, Thailand | clinical infectious diseases | oxford academic. Clin Infect Dis. 2016;62(3):383–91. doi:10.1093/cid/civ884.
   Web of Science ®Google Scholar
• Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou P-H, Linneman JG, Reed KD. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005;3(4):214–20. doi:10.3121/cmr.3.4.214.
   PubMedGoogle Scholar
• de Roux A, Marx A, Burkhardt O, Schweiger B, Borkowski A, Banzhoff A, Pletz M, Lode H. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine. 2006;24(10):1537–42. doi:10.1016/j.vaccine.2005.10.007.
   Web of Science ®Google Scholar
• Miossi R, Fuller R, Moraes JCB, Ribeiro ACM, Saad CGS, Aikawa NE, Miraglia JL, Ishida MA, Bonfá E, Caleiro MTC. et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics (Sao Paulo). 2013;68(2):129–34. doi:10.6061/clinics/2013(02)oa02.
   Web of Science ®Google Scholar
• van Assen S, Holvast A, Telgt D, Benne CA, de Haan A, Westra J, Kallenberg CGM, Bijl M. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine | elsevier enhanced reader. Clin Immunol. 2010;136(2):228–35. doi:10.1016/j.clim.2010.03.430.
   Web of Science ®Google Scholar
• Harpaz R, Dahl R, Dooling K. The prevalence of immunocompromised adults: United States, 2013. Open Forum Infect Dis. 2016;3(suppl_1). doi:10.1093/ofid/ofw172.1141.
   Google Scholar
• Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M. et al. Influenza vaccine effectiveness in the United States during the 2015–2016 season. N Engl J Med. 2017;377(6):534–43. doi:10.1056/NEJMoa1700153.
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM. et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014;58(3):319–27. doi:10.1093/cid/cit736.
   PubMed Web of Science ®Google Scholar
• McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman RK, Nowalk MP, Raviotta JM. et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529–40. doi:10.1093/infdis/jiu647.
   PubMed Web of Science ®Google Scholar
• Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP. et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013–2014 in the United States. J Infect Dis. 2016;213(10):1546–56. doi:10.1093/infdis/jiv577.
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M. et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis. 2016;63(12):1564–73. doi:10.1093/cid/ciw635.
   PubMed Web of Science ®Google Scholar
• CDC. People at High Risk of Flu. Centers for Disease Control and Prevention; 2022 September 6 [Accessed 2023 Mar 20]. https://www.cdc.gov/flu/highrisk/index.htm.
   Google Scholar
• Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML. et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2009;48(8):1003–32. doi:10.1086/598513.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100. doi:10.1093/cid/cit684.
   PubMed Web of Science ®Google Scholar
• Greenberg JA, Hohmann SF, Hall JB, Kress JP, David MZ. Validation of a method to identify immunocompromised patients with severe sepsis in administrative databases. Ann Am Thorac Soc. 2016;13(2):253–8. doi:10.1513/AnnalsATS.201507-415BC.
   PubMed Web of Science ®Google Scholar
• Hughes K, Middleton DB, Nowalk MP, Balasubramani GK, Martin ET, Gaglani M, Talbot HK, Patel MM, Ferdinands JM, Zimmerman RK. et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in immunocompromised adults. Clin Infect Dis. 2021;73(ciaa1927):4353–60. doi:10.1093/cid/ciaa1927.
   Google Scholar
• Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31(30):3104–9. doi:10.1016/j.vaccine.2013.04.026.
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184(5):345–53. doi:10.1093/aje/kww064.
   PubMed Web of Science ®Google Scholar
• Garten R, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN. et al. Update: influenza activity in the United States during the 2017–18 Season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2018;67(22):634–42. doi:10.15585/mmwr.mm6722a4.
   PubMed Web of Science ®Google Scholar
• Bodner K, Knight J, Hamilton MA, Mishra S. Testing if higher contact among vaccinated can be a mechanism for observed negative vaccine effectiveness. Am J Epidemiol. March 9, 2023:kwad055. doi:10.1093/aje/kwad055.
   Web of Science ®Google Scholar
• Glasziou P, McCaffery K, Cvejic E, Batcup C, Ayre J, Pickles K, Bonner C. Testing behaviour may bias observational studies of vaccine effectiveness. J Assoc Med Microbiol Infect Dis Can. 2022;7(3):242–6. doi:10.3138/jammi-2022-0002.
   Google Scholar
• Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ. et al. Waning of vaccine effectiveness against moderate and severe COVID-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 October 3;e072141. doi:10.1136/bmj-2022-072141.
   Google Scholar
• Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group a, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206(8):1250–9. doi:10.1093/infdis/jis487.
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Patricia Nowalk M, Dauer K, Clarke L, Raviotta JM, Balasubramani GK. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design. Vaccine. 2023;41(35):5134–40. doi:10.1016/j.vaccine.2023.06.056.
   Web of Science ®Google Scholar
• Hsiao A, Yee A, Fireman B, Hansen J, Lewis N, Klein NP. Recombinant or standard-dose influenza vaccine in adults under 65 years of age. N Engl J Med. 2023;389(24):2245–55. doi:10.1056/NEJMoa2302099.
   Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2017–18 influenza season. Am J Transplant. 2017;17(11):2970–82. doi:10.1111/ajt.14511.
   Web of Science ®Google Scholar
• Godoy P, Romero A, Soldevila N, Torner N, Jané M, Martínez A, Caylà JA, Rius C, Domínguez A. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Eurosurveillance. 2018;23(43):1700732. doi:10.2807/1560-7917.ES.2018.23.43.1700732.
   Web of Science ®Google Scholar
• Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Nato Adv Sci Inst Se. 2023;11(10):1525. doi:10.3390/vaccines11101525.
   Google Scholar